ranibizumab (lucentis0) and proliferative diabetic retinopathy

首页> 外文期刊>Prescrire international >ranibizumab (lucentis0) and proliferative diabetic retinopathy

【24h】

ranibizumab (lucentis0) and proliferative diabetic retinopathy

机译：Ranibizumab（Lucentis0）和增殖性糖尿病视网膜病变

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

In patients with proliferative diabetic retinopathy, the standard treatment is panretinal laser photocoagulation. Ranibizumab, which was already authorised in the European Union mainly for treating loss of visual acuity due to diabetic macular oedema, has now also been authorised for diabetic patients with proliferative retinopathy. Clinical evaluation of ranibizumab in this setting is based on one non-blinded randomised trial in 305 diabetic adults in which it was compared to panretinal laser photocoagulation. At the end of this trial, it was not shown to have either superior efficacy, or a lower incidence of ocular adverse effects, compared to laser therapy. As with all VEGF inhibitors, ranibizumab carries a risk of cardiovascular adverse effects, which is not the case with laser therapy.

机译：增生性糖尿病视网膜病变患者的标准治疗方法是全视网膜激光光凝。雷尼珠单抗已经在欧盟获得授权，主要用于治疗糖尿病性黄斑水肿导致的视力丧失，现在也被授权用于患有增殖性视网膜病变的糖尿病患者。在这种情况下，雷尼珠单抗的临床评估是基于一项对305名糖尿病成年人进行的非盲随机试验，在该试验中，雷尼珠单抗与全视网膜激光光凝进行了比较。在本试验结束时，与激光治疗相比，它既没有显示出更好的疗效，也没有显示出更低的眼部不良反应发生率。与所有VEGF抑制剂一样，雷尼珠单抗也有心血管不良反应的风险，而激光治疗的情况并非如此。

著录项

来源
《Prescrire international》 |2021年第226期|共1页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药学;
关键词

相似文献

外文文献
中文文献
专利

1. Prevalence of diabetic retinopathy, proliferative diabetic retinopathy and non-proliferative diabetic retinopathy in Asian T2DM patients: a systematic review and Metaanalysis [J] . Qian-Hui Yang1, Yan Zhang1, Xiao-Min Zhang1, 国际眼科杂志：英文版 . 2019,第002期
2. Optical coherence tomography angiography assessment of 577 nm laser effect on severe non-proliferative diabetic retinopathy with diabetic macular edema [J] . Zi-Jing Li, Jian-Hui Xiao, Peng Zeng, 国际眼科杂志：英文版 . 2020,第008期
3. Ocular surface changes in type II diabetic patients with proliferative diabetic retinopathy [J] . Yan, Gao, Yan, 国际眼科杂志：英文版 . 2015,第002期
4. Effects of laser photocoagulation on serum angiopoietin-1, angiopoietin-2, angiopoietin-1/angiopoietin-2 ratio, and soluble angiopoietin receptor Tie-2 levels in type 2 diabetic patients with proliferative diabetic retinopathy [J] . Qiao-Ying, You, Fu-Yuan, 国际眼科杂志：英文版 . 2014,第004期
5. Cost-effectiveness of Intravitreous Ranibizumab Compared With Panretinal Photocoagulation for Proliferative Diabetic Retinopathy Secondary Analysis From a Diabetic Retinopathy Clinical Research Network Randomized Clinical Trial [J] . Hutton David W., Stein Joshua D., Bressler Neil M., JAMA ophthalmology . 2017,第6期

机译：与糖尿病视网膜病变临床研究网络随机化临床试验的增殖性糖尿病性视网膜病变二次分析的PANRetinal ranibizumab的成本效益
6. Writing Committee for the Diabetic Retinopathy Clinical Research Network. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial (vol 314, pg 2137, 2015) [J] . Gross J. G., Glassman A. R., Jampol L. M. JAMA: the Journal of the American Medical Association . 2016,第9期

机译：糖尿病视网膜病临床研究网络写作委员会。 Panretinal Photocoilulation VS含有增殖性糖尿病视网膜病变的膀胱内植物疗法：随机临床试验（Vol 314，PG 2137,2015）
7. Ranibizumab induces regression of diabetic retinopathy (DR) in more than three-quarters of patients with high-risk non-proliferative diabetic retinopathy (NPDR) independent of retinal nonperfusion [J] . Wykoff Charles Clifton, Gune Shamika, Hill Lauren, Investigative ophthalmology & visual science . 2016,第12期

机译：Ranibizumab诱导糖尿病视网膜病变（DR）在超过四分之三的高风险不增殖性糖尿病视网膜病变（NPDR）中的糖尿病视网膜病（DR）的回归，与视网膜不灌注
8. Determination of Non-Proliferative and Proliferative Diabetic Retinopathy through Fundoscopy using Principal Component Analysis [C] . Carlos C. Hortinela, Jessie R. Balbin, Glenn V. Magwili, International Conference on Humanoid, Nanotechnology, Information Technology, Communication and Control, Environment, and Management . 2020

机译：利用主成分分析测定通过基底诊断的非增殖性和增殖性糖尿病视网膜病变
9. Effect of intravitreal or sub-tenon triamcinolone acetonide injection at completion of vitrectomy on peripheral retinochoroidal thickness in eyes with proliferative diabetic retinopathy [D] . Fujiwara Yoshito, 藤原圭人 2019

机译：玻璃体切除术完成后玻璃体内或肌腱下注射丙酮酸曲安奈德对增生性糖尿病性视网膜病变的眼睛周围脉络膜脉络膜厚度的影响
10. Ranibizumab Pretreatment in Vitrectomy with Internal Limiting Membrane Peeling on Diabetic Macular Edema in Severe Proliferative Diabetic Retinopathy [O] . Jian Guan, Na Cai, Li-Min Liu, 2020

机译：雷尼珠单抗在玻璃体切除术中预处理与严重局限性糖尿病性视网膜病变中的糖尿病性黄斑水肿的内部限制膜剥离
11. Ranibizumab Pretreatment in Vitrectomy with Internal Limiting Membrane Peeling on Diabetic Macular Edema in Severe Proliferative Diabetic Retinopathy [O] . Jian Guan, Na Cai, Li-Min Liu, 2020

机译：Ranibizumab在玻璃体切除术中的预处理，内部限制性膜剥落在糖尿病性糖尿病视网膜病变中的糖尿病黄斑水肿
12. New Therapeutic Window of Regenerative Opportunity in Diabetic Retinopathy by VESGEN Analysis. [R] . Parsons-Wingert, P. A. 2012

机译：VEsGEN分析糖尿病视网膜病变再生机会的新治疗窗。

ranibizumab (lucentis0) and proliferative diabetic retinopathy

摘要

著录项

相似文献

相关主题

期刊订阅